Lorkaserin
Idi na navigaciju
Idi na pretragu
| |||
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| (1R)-8-hloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin | |||
| Klinički podaci | |||
| Robne marke | Belviq | ||
| Identifikatori | |||
| CAS broj | 846589-98-8 | ||
| ATC kod | nije dodeljen | ||
| PubChem[1][2] | 11658860 | ||
| ChemSpider[3] | 9833595 | ||
| UNII | 637E494O0Z 
| ||
| ChEMBL[4] | CHEMBL360328
| ||
| Hemijski podaci | |||
| Formula | C11H14ClN | ||
| Mol. masa | 195,688 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakoinformacioni podaci | |||
| Licenca | |||
| Trudnoća | X(US) | ||
| Pravni status | ℞-only (SAD) | ||
| Način primene | Oralno | ||
Lorcaserin (APD-356, Belviq,[5][6], Lorqess[7][8]) je lek protiv gojaznosti. On ima serotonergička svojstva i deluje kao anoreksik. FDA nije odobrila njegovu primenu 2010, zbog zabrinutosti za bezbednost i efikasnost leka.[9] [10]
Vidi još[uredi - уреди | uredi kôd]
Reference[uredi - уреди | uredi kôd]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ „FDA approves Arena obesity drug; first in 13 years”. Reuters. 27. 6. 2012.. Arhivirano iz originala 2014-07-27. https://web.archive.org/web/20140727213357/http://www.reuters.com/article/2012/06/27/us-arena-obesity-idUSBRE85Q1AA20120627.
- ↑ „Belviq”. Trademarkia. 23 Jun 2011. http://www.trademarkia.com/belviq-85354490.html. Pristupljeno 27. 6. 2012.
- ↑ „Lorqess”. EvaluatePharma. 7. 9. 2010.. http://www.evaluatepharma.com/Universal/View.aspx?type=Entity&entityType=Product&id=43487&lType=modData&componentID=1002. Pristupljeno 13. 9. 2010.
- ↑ „Lorqess”. Trademarkia. 25. 3. 2010.. http://www.trademarkia.com/lorqess-77968131.html. Pristupljeno 13. 9. 2010.
- ↑ Andrew Pollack (16. 9. 2010.). „F.D.A. Panel Urges Denial of Diet Drug”. New York Times. http://www.nytimes.com/2010/09/17/health/17drug.html?hpw.
- ↑ „FDA Issues Complete Response Letter for Lorcaserin New Drug Application”. 23. 10. 2010.. http://www.prnewswire.com/news-releases/fda-issues-complete-response-letter-for-lorcaserin-new-drug-application-105586113.html.
Spoljašnje veze[uredi - уреди | uredi kôd]
